TLDR

MARKET RECAP → The S&P 500 (VOO) closed slightly higher Monday ahead of the Fed’s interest rate decision on Wednesday (9/18), where markets are pricing in a 0.25%-0.50% rate cut.

AMAZON DEMANDS FULL RETURN TO OFFICE→ ✈️ Amazon (AMZN) CEO Andy Jassy told employees to get back to the office five days a week or reconsider their future at the company. 💼 He stressed that in-person work boosts collaboration, culture, and innovation.

RACE FOR RADIOTHERAPY DOMINANCE HEATS UP → Novartis (NVS) leads the charge in radiopharmaceuticals, but competitors like Eli Lilly (LLY) and BMS are making big acquisitions to catch up. 💥 The battle for this cancer-fighting tech is intensifying, with huge investments in both drugs and manufacturing capacity.

Was this email forwarded to you? Sign up for free here.

MARKETS

Today’s S&P 500 Heatmap

Notable Earnings This Week

TODAY’S TOP NEWS

Amazon Demands Full Return To Office

💼 Amazon (AMZN) CEO Andy Jassy told employees they must return to the office five days a week, ending the previous hybrid model. He emphasized that in-person work fosters better collaboration, innovation, and stronger connections to company culture.

🏢 Jassy highlighted that employees who can’t commit to this new structure might need to reconsider their future at Amazon, underscoring the importance of being physically present for optimal performance.

🔄 The decision sparked significant employee pushback, but Jassy made it clear that returning to office life was critical for maintaining Amazon’s competitive edge and success.

TODAY’S TOP NEWS

Race For Radiotherapy Dominance Heats Up

💊 Novartis (NVS) remained the leader in radiopharmaceuticals, driven by its blockbuster drug Pluvicto, which delivers targeted radiation to cancer cells. Despite manufacturing hiccups, Novartis built a vast network to meet growing demand.

📈 Competitors like Eli Lilly (LLY) and Bristol Myers Squibb (BMY) jumped into the race, acquiring smaller players with promising technologies to challenge Novartis’ head start in this booming cancer treatment field.

⚛️ With demand for radioligand therapies surging, pharmaceutical companies rushed to build manufacturing capacity, signaling a nuclear push into personalized cancer treatments​.

BULL VS. BEAR

NOTABLE POSTS

KEEP READING

Charter rolls out new Spectrum pricing and internet speeds, aims to ‘be a better service operator’ (CNBC)

BlackRock’s Rick Rieder says a golden age for fixed income begins this week with the Fed rate cut (CNBC)

UAW union files unfair labor charges against Stellantis, accuses automaker of violating contract (CNBC)

Air Canada reaches last-minute deal with pilots union, averting strike (CNN)

Is “Spending FOMO” Secretly Sabotaging Your Savings? (ML)

How This 25-Year-Old Built a Six-Figure Creator Business Just One Year After Quitting Her Job (ML)

WHAT WE’RE WATCHING

OUR FAVORITE TOOLS & RESOURCES

• Earnings Hub — Earnings calendar (NEW ADDITION)

• Quiver Quantitative — Quiver allows retail investors to tap into the power of big data with insights into things like congressional trades as they are disclosed

• Perplexity — Perplexity AI is an AI-chatbot-powered research and conversational search engine

• The Market Ear — Live news, analysis and commentary on what moves markets and trading

• Coinmarketcap.com — Crypto market data

• Finviz — Financial visualizations

• Trading Economics — Economic calendar

• CME FedWatch Tool — Market-implied probabilities of future levels of interest rates 

• Dataroma — Track stock picks and portfolios of legendary value investors such as Warren Buffett

• ChatGPT — Large language model-based chatbot powered by generative AI

• Vimcal — Lightning-fast calendar and AI scheduling assistant

^{_{The Bull vs. Bear Merchandise Promotion is a limited time campaign that begins on December 1, 2023 at 12:00 AM ET and ends on the date that there are no more Rewards. This Promotion is available to any registered MoneyLion user who is a legal resident of the 50 United States or the District of Columbia and who has reached the age of majority in their state as of the beginning of the Promotional Period. See terms and conditions here.}}

<sup><sub>This advertising email was sent to you because you have a MoneyLion account. If you would like to unsubscribe, please do so using this link. We respect your right to privacy. Please do not reply to this email with sensitive information, such as an account number, Social Security number, date of birth, bank account information, PIN, password, or Online ID. The security and confidentiality of your personal information is important to us. If you have any questions or want to read more, please visit our Help Center.

MoneyLion and Pathward do not provide, nor do they guarantee, any third-party product, service, information, or recommendation. The third parties providing these products or services are solely responsible for them, as well as all other content on their websites. MoneyLion is not liable for any third party’s failure with regard to those advertised products, services, and benefits. These advertised products and services may not be FDIC insured or bank-guaranteed, and may be subject to a different privacy policy than MoneyLion’s. You should check individual offers, products, and services to become familiar with any applicable restrictions or conditions that may apply. MoneyLion may receive compensation from third parties for referring you to the third party, their products or to their website.

The influencer, creator and other content provided in the MoneyLion App (“Content”) is for informational and entertainment purposes only and should not be construed as legal, tax, investment, financial, or other advice. All Content is intended to be of a general nature, does not address the circumstances of any particular individual or entity, and may not constitute a comprehensive or complete statement of the matters discussed. MoneyLion is not a fiduciary by virtue of any person’s use of or reliance on the Content. You should consult an appropriate professional if you require any legal, tax, investment, financial or other advice. Terms and Conditions for our subscriber referral can be found here.</sub></sup>